Counteracting Age-related Loss of Skeletal Muscle Mass

NCT ID: NCT02034760

Last Updated: 2019-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

208 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-10

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Up to approximately 205 (dependent on drop-out rate) healthy elderly individuals (at least 65 years old) are recruited as subjects.

Upon inclusion, each individual will be randomized into one of the five groups stratified according to gender (M/F) and 30s chair stand (\<16 OR ≥16). The five groups are: Heavy Resistance Training (N=30-35), Light Intensity Training (N=30-35), Protein Whey (N=40-50), Protein Collagen (N=40-50) and Carbohydrate (N=30-35). The individuals randomized into one of the supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded to the supplement content.

Assessments will be performed at Baseline (before intervention start), and after 6 and 12 months of intervention and again at 18 months (after 6 months of follow up).

The primary outcome is change in quadriceps muscle cross sectional area from Baseline to 12 months of intervention.

The primary hypothesis is that by applying the intension-to-treat analysis, the Light Intensity Training group will increase quadriceps muscle cross sectional area just as much as the Heavy Resistance Training group. The two training groups will gain more muscle mass than the Protein Whey group, which will gain more than the Protein Collagen and the Carbohydrate groups that will loose quadriceps muscle cross sectional areas.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Muscle Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heavy Resistance Training

Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Group Type ACTIVE_COMPARATOR

Heavy Resistance Training

Intervention Type PROCEDURE

Supervised Heavy Resistance Training three times weekly for 52 weeks.

Protein Whey

Intervention Type DIETARY_SUPPLEMENT

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Light Intensity Training

Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Group Type EXPERIMENTAL

Light Intensity Training

Intervention Type PROCEDURE

Home-based Light Intensity Training three-five times weekly for 52 weeks.

Protein Whey

Intervention Type DIETARY_SUPPLEMENT

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Protein Whey

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Group Type ACTIVE_COMPARATOR

Protein Whey

Intervention Type DIETARY_SUPPLEMENT

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Protein Collagen

Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.

Group Type ACTIVE_COMPARATOR

Protein Collagen

Intervention Type DIETARY_SUPPLEMENT

Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.

Carbohydrate

Two daily 30g carbohydrate supplementations for 52 weeks.

Group Type PLACEBO_COMPARATOR

Carbohydrate

Intervention Type DIETARY_SUPPLEMENT

Two daily 30g carbohydrate supplementations for 52 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heavy Resistance Training

Supervised Heavy Resistance Training three times weekly for 52 weeks.

Intervention Type PROCEDURE

Light Intensity Training

Home-based Light Intensity Training three-five times weekly for 52 weeks.

Intervention Type PROCEDURE

Protein Whey

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

Intervention Type DIETARY_SUPPLEMENT

Protein Collagen

Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.

Intervention Type DIETARY_SUPPLEMENT

Carbohydrate

Two daily 30g carbohydrate supplementations for 52 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, independently living
* Age at least 65 years

Exclusion Criteria

* Subjects dependent on help/nursing etc.
* Chronic medical diseases: Diabetes mellitus, clinical knee or hip osteoarthritis, other types of arthritis or connective tissue disorders, active cancer, renal diseases, severe chronic obstructive pulmonary disease, cardiac arrhythmias or known decreased left ventricular ejection fraction, lactose or gluten intolerance, chronic inflammatory bowel diseases, non-treated hyper/hypothyroidism, dementia.
* Surgical diseases: Bone, muscle, tendon or joint injuries compromising participation in exercise regimens.
* Implanted magnetic devices incompatible with MRi-scanning.
* Weekly alcohol consumption \> 21 units (1 unit equals 4g of ethanol) for men and \> 14 for women.
* Medicine except acetylsalicylic acid, paracetamol, thyroid function hormones, statins in doses above 40mg/day or if combined with subjective myalgia, ACE-inhibitors, Angiotensin II blockers, beta-blockers, calciumantagonists, proton-pump inhibitors, thiazides, potassium-sparing diuretics and loop diuretics.
* \>1 hour of exercise weekly, except light activities such as stretching/gymnastics and bike-riding/walking as transportation.
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role collaborator

Arla Foods

INDUSTRY

Sponsor Role collaborator

Bispebjerg Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lars Holm

Ph.D. M.S.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rasmus Bechshøft, Ph.d. stud

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Lars Holm, Assoc. prof.

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Michael Kjaer, MD, Proff.

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Søren Reitelseder, Ph.d.

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Jacob Bülow, MD PhD stud

Role: PRINCIPAL_INVESTIGATOR

Bispebjerg Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bispbebjerg Hospital

Copenhagen NV, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Mertz KH, Reitelseder S, Rasmussen MA, Bulow J, Hojfeldt G, Jensen M, Hjulmand M, Lindberg J, Kramer MU, Bechshoft R, Holm L. Changes in Muscle Mass and Strength During Follow-Up After One-Year Resistance Training Interventions in Older Adults. J Strength Cond Res. 2023 Oct 1;37(10):2064-2070. doi: 10.1519/JSC.0000000000004517. Epub 2023 Jul 17.

Reference Type DERIVED
PMID: 37463344 (View on PubMed)

Mertz KH, Reitelseder S, Bechshoeft R, Bulow J, Hojfeldt G, Jensen M, Schacht SR, Lind MV, Rasmussen MA, Mikkelsen UR, Tetens I, Engelsen SB, Nielsen DS, Jespersen AP, Holm L. The effect of daily protein supplementation, with or without resistance training for 1 year, on muscle size, strength, and function in healthy older adults: A randomized controlled trial. Am J Clin Nutr. 2021 Apr 6;113(4):790-800. doi: 10.1093/ajcn/nqaa372.

Reference Type DERIVED
PMID: 33564844 (View on PubMed)

Bechshoft RL, Reitelseder S, Hojfeldt G, Castro-Mejia JL, Khakimov B, Ahmad HF, Kjaer M, Engelsen SB, Johansen SM, Rasmussen MA, Lassen AJ, Jensen T, Beyer N, Serena A, Perez-Cueto FJ, Nielsen DS, Jespersen AP, Holm L. Counteracting Age-related Loss of Skeletal Muscle Mass: a clinical and ethnological trial on the role of protein supplementation and training load (CALM Intervention Study): study protocol for a randomized controlled trial. Trials. 2016 Aug 9;17(1):397. doi: 10.1186/s13063-016-1512-0.

Reference Type DERIVED
PMID: 27507236 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-4-2013-070

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.